EGFR and cancer: Sym004, the mixture of two monoclonal anti-EGFR antibodies, induced removal of the receptor from the cancer cell surface by triggering EGFR internalization and degradation, and was effective in treatment of Cetuximab-resistant tumors (Pedersen et al., 2010; Iida et al., 2013).